GH Research PLC - (GHRS) closed at $19.10 on November 13, 2026, up 3.3% from the previous close, on volume of 552,308 shares (30-day average 302,155).
Data as of November 13, 2026.
13-Nov-2026
GH Research GAAP EPS of -$0.18 beats by $0.13
Seeking Alpha News (Fri, 13-Nov 11:30 AM ET)
GH Research Reports Third-Quarter 2026 Results and Business Updates
TipRanks (Fri, 13-Nov 8:47 AM ET)
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Fri, 13-Nov 8:00 AM ET)
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
Globe Newswire (Fri, 13-Nov 7:55 AM ET)
U.S. funding to support studies into psychedelic drug ibogaine in PTSD
Seeking Alpha News (Thu, 12-Nov 12:47 PM ET)
Market Chameleon (Mon, 20-Apr 7:07 AM ET)
Market Chameleon (Mon, 20-Apr 5:17 AM ET)
Market Chameleon (Mon, 5-Jan 2:05 AM ET)
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
GH Research PLC - trades on the NASDAQ stock market under the symbol GHRS.
As of November 13, 2026, GHRS stock price climbed to $19.10 with 552,308 million shares trading.
GHRS has a beta of 1.63, meaning it tends to be more sensitive to market movements. GHRS has a correlation of 0.12 to the broad based SPY ETF.
GHRS has a market cap of $1.31 billion. This is considered a Small Cap stock.
In the last 3 years, GHRS traded as high as $31.44 and as low as $5.05.
The top ETF exchange traded funds that GHRS belongs to (by Net Assets): IBB, PSIL, EIRL, BBC, IBBQ.
GHRS has outperformed the market in the last year with a return of +39.2%, while the SPY ETF gained +13.4%. However, in the most recent history, GHRS shares have underperformed the stock market with its stock returning -32.2% in the last 3 month period and -8.4% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
GHRS support price is $17.64 and resistance is $19.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GHRS shares will trade within this expected range on the day.